Tejara Capital Ltd Buys Shares of 113,084 Arcutis Biotherapeutics, Inc. $ARQT
Tejara Capital Ltd has acquired a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), purchasing 113,084 shares valued at approximately $2.965 million, making it their 24th biggest holding. Several other hedge funds also adjusted their stakes in ARQT, while company insiders sold shares totaling over $288,000. Analyst ratings indicate a "Moderate Buy" consensus with an average price target of $35.57.
Arcutis (NASDAQ: ARQT) director to sell 1,072 shares
A director at Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), Terrie Curran, has filed a Rule 144 notice to sell 1,072 shares of the company's common stock. These shares, valued at $27,912.35, were acquired through a stock option exercise on May 31, 2023, and are planned to be sold via Merrill Lynch on the NASDAQ. This filing indicates an insider transaction and is considered to have a neutral impact and sentiment.
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,730 Shares
Arcutis Biotherapeutics Director Howard Welgus sold 4,730 shares of the company's stock for $123,831.40, reducing his ownership by 11.48%. This transaction occurred under a Rule 10b5-1 trading plan. The company recently reported strong quarterly earnings of $0.11 per share and revenue of $129.86 million, both exceeding analyst expectations.
Arcutis (NASDAQ: ARQT) officer to sell 1,697 shares after recent August trades
Arcutis Biotherapeutics officer Patrick Burnett plans to sell 1,697 shares of common stock, valued at approximately $45,819, as detailed in a recent SEC Form 144 filing. This proposed sale follows prior transactions in August where Burnett sold significant blocks of shares. The filing also notes that the shares are associated with a restricted stock vest on August 18, 2026.
Arcutis (NASDAQ: ARQT) holder plans $123,834 August sale
Howard Welgus has filed a Form 144 indicating an upcoming sale of 4,730 shares of Arcutis Biotherapeutics (NASDAQ: ARQT) common stock, valued at $123,834.71, through Merrill Lynch on or after August 17, 2026. These shares are linked to restricted stock vesting and stock option exercises from various dates. Welgus has also reported several sales of ARQT shares in the preceding three months.
Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action?
Arcutis Biotherapeutics (ARQT) reported strong Q2 2026 results with $129.86 million in revenue and $15.01 million in net income, leading management to raise full-year 2026 net product sales guidance to $525 million–$540 million. This performance, coupled with the chief commercial officer's resignation, reinforces confidence in ZORYVE's uptake and suggests Arcutis's commercial execution is ahead of schedule. While the higher sales outlook is positive, investors should consider the company's concentrated revenue base, potential generic pressure, and narrow internal pipeline when evaluating its long-term growth durability.
Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G
Polar Capital Holdings Plc and Polar Capital LLP have disclosed a 5.28% ownership stake in Arcutis Biotherapeutics, Inc. (ARQT) through a Schedule 13G filing. The investment firm beneficially owns 6,606,945 shares, with sole voting and dispositive power, based on Arcutis's 125,083,374 outstanding shares as of May 6, 2026. This filing indicates a passive investment intent, with the aggregated amount beneficially owned representing 5.28% of the class.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 million. Despite positive analyst sentiment and strong financial performance, company insiders have sold approximately $803,066 worth of shares in the past 90 days.
Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock
Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ: ARQT), sold $394,896 worth of company stock across two transactions on August 11 and 12, 2026, after exercising stock options. These sales occurred at weighted average prices around $26.52 and $26.08, following options exercised at $3.64 per share. Arcutis Biotherapeutics recently reported strong Q2 2026 financial results, with net product revenue exceeding forecasts, leading Guggenheim to raise its price target for the company.
Patrick Burnett Sells 8,300 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 8,300 shares of the company's stock on August 11th at an average price of $26.52, totaling $220,116. This transaction reduced his ownership by 6.51% and follows other sales in early August. Despite the insider selling, analysts maintain a "Moderate Buy" consensus rating with a target price of $35.57, driven by recent quarterly results that exceeded revenue and EPS expectations.
Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 6,700 shares of the company's stock for $174,736 on August 12th, reducing his direct stake by over 5%. This sale follows two earlier transactions in August where he sold an additional 9,255 shares. Despite the insider selling, analyst sentiment for ARQT remains positive with a "Moderate Buy" consensus and an average price target of $35.57, driven by recent quarterly results that exceeded expectations.
Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com
Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 results showed a significant revenue increase, leading Guggenheim to raise its price target. Arcutis Biotherapeutics appears undervalued according to InvestingPro analysis, despite a strong gross profit margin.
Bank of America Corp DE Acquires 547,835 Shares of Arcutis Biotherapeutics, Inc. $ARQT
Bank of America Corp DE significantly increased its stake in Arcutis Biotherapeutics by 32.7%, acquiring an additional 547,835 shares, bringing its total to 2.22 million shares valued at $52.3 million. This move comes as analysts maintain a "Moderate Buy" rating for ARQT, with several firms raising their price targets following strong Q1 earnings where the company surpassed revenue and EPS expectations. Other institutional investors have also increased their positions in Arcutis, despite some insider selling activity.
Arcutis insider plans sale of 15,000 shares | ARQT SEC Filing - Form 144
Arcutis Biotherapeutics (ARQT) insider Patrick Burnett has filed a Form 144 to sell 15,000 shares of common stock through Merrill Lynch on or after August 11, 2026. These shares were acquired via a stock option exercise on January 12, 2024. Burnett previously sold 955 shares on August 3, 2026, for $24,941.54.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics announced the grant of 143,500 restricted stock units (RSUs) and options to purchase 37,000 shares to 24 new employees. These inducement awards were made under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 3, 2026. The RSUs and stock options will vest over four years, subject to continued employment, and the stock options have an exercise price of $25.94 per share.
State Street Corporation (ARQT) discloses 4.7% beneficial stake in Arcutis
State Street Corporation has disclosed a 4.7% beneficial ownership stake in Arcutis Biotherapeutics, Inc., amounting to 5,822,840 shares. The filing, a SCHEDULE 13G, indicates that State Street and its investment adviser affiliates collectively manage these shares with shared voting power over 5,507,182 shares and shared dispositive power over all 5,822,840 shares. This disclosure falls under the "ownership of 5 percent or less of a class" category, with Elizabeth Schaefer, Senior Vice President, Chief Accounting Officer, signing the report.
24 New Arcutis Employees Get Stock Awards That Vest Over Four Years
Arcutis Biotherapeutics (Nasdaq: ARQT) has granted 143,500 restricted stock units (RSUs) and options to purchase 37,000 shares to 24 new hires. These inducement grants, effective August 3, 2026, vest over four years, subject to continued employment, and were made in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term with an exercise price of $25.94 per share, matching the closing price on August 3, 2026.
Arcutis Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $36.62, Implies 35% Upside
Arcutis Biotherapeutics, Inc. (ARQT) has seen its average 12-month price target raised from $34.62 to $36.62 by 8 analysts, suggesting a 35% potential upside from its August 5 closing price. The consensus rating for ARQT remains "Buy," with 7 Buys and 1 Hold among covering analysts.
Arcutis Biotherapeutics, Inc. 2026: Revenue $129.86M, EPS $0.11— 10-Q Summary
Arcutis Biotherapeutics, Inc. reported strong results for the 2026 quarter, with revenue reaching $129.86M and diluted EPS at $0.11, significantly exceeding the prior year's performance. The growth was primarily driven by increased product demand, successful label expansions, and a strategic shift to an internal commercial team. The company also saw substantial year-to-date product net sales growth and positive clinical pipeline advancements.
Did Profitability, Higher 2026 Guidance, and New Commercial Leadership Just Recast Arcutis Biotherapeutics' (ARQT) Investment Narrative?
Arcutis Biotherapeutics (ARQT) recently announced its chief commercial officer's resignation, yet reported strong second-quarter 2026 revenue of US$129.86 million and net income of US$15.01 million, alongside raising its full-year 2026 net product sales guidance to US$525 million–US$540 million. The company is also bringing in Robert Lisicki, an experienced commercial leader, suggesting a shift in its investment narrative towards sustained ZORYVE expansion and profitability despite concentration risk. Analysts project significant revenue and earnings growth by 2029, with a fair value estimate indicating a potential 28% upside.
Arcutis Biotherapeutics EVP Burnett sells $24,941 in stock
Patrick Burnett, EVP and Chief Medical Officer at Arcutis Biotherapeutics (NASDAQ: ARQT), sold 955 shares of company stock for $24,941 to cover tax withholding obligations. The sale occurred on August 3, 2026, at an average price of $26.1168 per share. Despite this sale, ARQT shares have seen a strong 76% return over the past year, and the company recently reported increased Q2 revenue and profitability.
Form 4 Arcutis Biotherapeutics Inc For: 6 August By Investing.com
This article reports on the filing of Form 4 for Arcutis Biotherapeutics Inc. on August 6, 2026. Form 4 filings disclose changes in beneficial ownership of company securities by insiders. The brief news item indicates that this information was published by Investing.com.
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
Arcutis President and CEO Todd Watanabe sold 4,375 shares for $114,275 on August 3, 2026. This transaction was non-discretionary, executed to cover tax obligations from vested restricted stock units, and does not reflect a change in his outlook for the company. Arcutis Biotherapeutics reported profitability in Q2 2026 with a net income of $15 million and raised its full-year 2026 net product sales guidance.
Earnings call transcript: Arcutis Biotherapeutics tops Q2 2026 revenue view
Arcutis Biotherapeutics reported strong Q2 2026 results, surpassing revenue expectations and achieving profitability due to robust demand for its dermatology product, ZORYVE. The company raised its full-year 2026 revenue guidance to $525 million-$540 million, driven by continued prescription growth, recent FDA approvals for ZORYVE in pediatric psoriasis, and strategic investments in sales force expansion and patient access initiatives. Arcutis also highlighted progress in its pipeline, including trials for vitiligo and hidradenitis suppurativa, and the advancement of ARQ-234 for atopic dermatitis.
Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Call Summary
Arcutis Biotherapeutics, Inc. reported a significant turnaround in Q2 2026, with a 59% year-over-year revenue increase driven by strong ZORYVE franchise demand and the successful conversion from topical steroids. The company raised its full-year sales guidance to $525 million–$540 million, expecting continued growth from sales force expansion, a new primary care team, and a virtual health platform. Arcutis also achieved positive net income and is pursuing pipeline expansion and a PDUFA date for ZORYVE cream in infants.
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates
Arcutis Biotherapeutics (ARQT) reported Q2 earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.09, and revenues of $129.86 million, surpassing estimates by 6.57%. Despite the strong quarterly performance, the stock has underperformed the S&P 500 year-to-date. The company currently holds a Zacks Rank #2 (Buy), indicating expected market outperformance.
Earnings Flash (ARQT) Arcutis Biotherapeutics, Inc. Reports Q2 Revenue $129.9M, vs. FactSet Est of $118.9M
Arcutis Biotherapeutics, Inc. (ARQT) reported Q2 revenue of $129.9 million, surpassing the FactSet estimate of $118.9 million. The company is a commercial-stage medical dermatology company with a product portfolio including ZORYVE Roflumilast Cream and Foam. Arcutis Biotherapeutics also announced executive changes and raised its sales guidance for the full year 2026.
Price to book forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT
The article focuses on the "Price to book forward" financial metric for Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT). It appears to be a financial data point or analysis page from TradingView, indicating the company's financial overview without providing specific numerical data in the provided text. The content highlights the stock on the Nasdaq Stock Market and mentions various financial and market data resources used by TradingView.
Pediatric Dermatology’s Blind Spot: How Arcutis Built a Drug Pipeline Where the Industry Wouldn’t Look
Arcutis Biotherapeutics focused on pediatric dermatology, a market largely abandoned by larger companies, by prioritizing clinical insights and engaging collaboratively with the FDA. Their drug, ZORYVE (roflumilast), has undergone a disciplined age-extension program, targeting various age groups down to infants as young as three months. Arcutis leveraged a unique approach to pricing and telehealth to ensure broad patient access, differentiating themselves from competitors through a well-tolerated, once-daily cream formulation that avoids sensitizers and irritants.
Arcutis Biotherapeutics (ARQT) insider plans Rule 144 sale after prior stock disposal
Arcutis Biotherapeutics insider Todd F. Watanabe has filed a Rule 144 notice to sell 4,375 common shares that became eligible for sale through restricted stock vesting on August 1, 2026. This planned disposition follows a previous sale of 3,172 common shares on May 4, 2026, which generated proceeds of $74,892.82. The filing provides advance notice to investors about upcoming insider stock dispositions.
Arcutis Biotherapeutics (ARQT) insider Matsuda plans sale after stock vesting
Masaru Matsuda, an insider at Arcutis Biotherapeutics (ARQT), has filed a Form 144 to sell 1,230 shares of common stock. The sale is planned for August 3, 2026, through Merrill Lynch on NASDAQ, following the vesting of restricted stock on August 1, 2026. This filing also indicates that Matsuda previously sold 8,256 shares for over $192,000 on May 4, 2026.
Is Arcutis (ARQT) Quietly Reframing Its Strategy With Mirum CEO Chris Peetz on the Board?
Arcutis Biotherapeutics recently appointed Mirum Pharmaceuticals CEO Chris Peetz to its Board of Directors, a move that could subtly influence Arcutis's growth and capital allocation strategies. While the immediate focus remains on the ZORYVE franchise and its expanded FDA approval for pediatric plaque psoriasis, Peetz's expertise in rare diseases and M&A might signal a future broadening of Arcutis's pipeline or strategic partnerships. The company's financial projections indicate significant revenue and earnings growth, yet its heavy reliance on ZORYVE highlights the importance of market performance and controlled spending.
Is Arcutis (ARQT) Quietly Reframing Its Strategy With Mirum CEO Chris Peetz on the Board?
Arcutis Biotherapeutics recently appointed Chris Peetz, co-founder and CEO of Mirum Pharmaceuticals, to its Board of Directors. This move is significant because Peetz brings extensive experience in biopharmaceuticals, finance, and M&A, particularly in scaling rare-disease platforms and executing successful acquisitions. While the immediate focus for Arcutis remains on its ZORYVE franchise, Peetz's expertise could influence the company's long-term strategy regarding growth, partnerships, and capital allocation, especially given the company's reliance on ZORYVE and potential balance sheet pressures.
Is Arcutis (ARQT) Quietly Reframing Its Strategy With Mirum CEO Chris Peetz on the Board?
Arcutis Biotherapeutics (ARQT) recently appointed Chris Peetz, co-founder and CEO of Mirum Pharmaceuticals, to its Board of Directors. This move is expected to influence Arcutis's growth strategies, partnerships, and capital allocation, given Peetz's extensive experience in biopharmaceuticals, finance, and M&A, particularly in scaling rare-disease platforms. While the immediate focus remains on the ZORYVE franchise, Peetz's appointment strengthens governance and deal-making capabilities, suggesting a potential long-term strategic reframing for Arcutis.
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Arcutis Biotherapeutics, Inc. (ARQT) is expected to report a significant year-over-year increase in earnings and revenues for the quarter ending June 2026. The company has a positive Earnings ESP of +52.94% and a Zacks Rank of #2, indicating a high probability of beating the consensus EPS estimate. Investors should consider these factors along with the company's past surprise history when evaluating the stock ahead of its earnings release.
Arcutis Biotherapeutics Inc (ARQT) Institutional Confidence
Arcutis Biotherapeutics Inc (ARQT) shows a strong institutional shareholding score of 10.00, ranking 1st in the Pharmaceuticals industry despite a recent quarter-over-quarter decrease of 11.87% in institutional shareholding proportion. Ron Baron is the largest institutional shareholder, holding 1.19M shares. The article also lists other significant institutional shareholders and their recent activity.
ARQT|Arcutis Biotherapeutics Inc|Price:27.860|Chg%:+0.510
This article provides a comprehensive stock analysis of Arcutis Biotherapeutics Inc (ARQT) by TradingKey, highlighting its strong fundamentals, high growth potential, and "Buy" rating from analysts. It details the company's product portfolio, including ZORYVE for psoriasis and atopic dermatitis, and pipeline treatments for alopecia areata and hand eczema. The analysis covers the TradingKey Stock Score, institutional ownership, valuation, and peer comparison within the pharmaceuticals industry.
Arcutis Biotherapeutics Inc (ARQT) Balance Sheet
This article provides the quarterly and annual balance sheets for Arcutis Biotherapeutics Inc (ARQT), allowing users to assess the company's financial health, analyze fundamentals, and calculate key ratios. It details various assets, liabilities, and shareholder equity components, along with their year-over-year changes. The piece also includes an FAQ section answering common questions about balance sheet metrics and ARQT's specific financial figures.
Arcutis Biotherapeutics Inc (ARQT) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for Arcutis Biotherapeutics Inc (ARQT), allowing users to analyze its financial health. It includes data on operating, investing, and financing cash flows, along with explanations of these financial metrics. The document also presents frequently asked questions regarding cash flow analysis for ARQT.
Arcutis Biotherapeutics Inc (ARQT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Arcutis Biotherapeutics Inc (ARQT), focusing on its dividends and stock splits. It states that the company has not distributed any dividends over the past five years. The page also includes current stock prices, market capitalization, and links to financial data and company profiles.
Arcutis Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ARQT
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) generated $376.07 million USD in the last year, with its Dermatological Treatments segment being the sole contributor to this revenue. All of the company's revenue originated from the United States and Canada. This figure marks an increase from the $196.54 million USD reported in the previous year.
Loss-Making Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Set To Breakeven
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is expected to reach profitability by the end of 2026, with analysts forecasting a mean revenue of US$165.7m for that year. The company's cash runway is estimated to be over two years, alleviating immediate concerns about liquidity. However, investors should monitor cash burn given the relatively high rate compared to its market cap.
Enterprise value to revenue forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT
This article focuses on the enterprise value to revenue forward for Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT). It provides the company's stock information, indicating that the market is currently closed with no trades. The content highlights financial data sourced from ICE Data Services and FactSet.
Guggenheim Remains a Buy on Arcutis Biotherapeutics (ARQT)
Guggenheim reiterated a Buy rating for Arcutis Biotherapeutics (ARQT) with a $35.00 price target, following the company's Q1 revenue of $105.4 million and reduced GAAP net loss. While analyst consensus is a Strong Buy, recent insider sentiment has been negative due to increased selling activity. The report also highlights the launch of a new TipRanks ETF, NYSE:RANK.
Arcutis Biotherapeutics (ARQT) director receives RSUs and stock options
Arcutis Biotherapeutics director Christopher Peetz was granted Restricted Stock Units (RSUs) and stock options on July 15, 2026, as reported in a neutral filing. He received 4,315 RSUs set to vest by June 2027 or the next annual meeting, and stock options for a total of 34,496 shares with an exercise price of $27.78, vesting over several years. Additionally, The Peetz Family Trust indirectly holds 187,500 shares, for which he disclaims beneficial ownership beyond his pecuniary interest.
Arcutis Biotherapeutics (ARQT) director trades stock under 10b5-1 plan
Arcutis Biotherapeutics director Howard G. Welgus sold 4,730 shares of common stock at $26.91 per share and exercised stock options to acquire additional shares on July 15, 2026. These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on March 13, 2026. Following these trades, Welgus directly owned 37,109 shares of Common Stock.
Arcutis Biotherapeutics director sells $127,284 in stock
Howard G. Welgus, a director at Arcutis Biotherapeutics, Inc., sold 4,730 shares of common stock worth $127,284 on July 15, 2026, under a pre-arranged trading plan. On the same day, he also acquired 4,096 shares through exercising stock options, totaling $32,474. The company has also recently announced an expanded FDA approval for Zoryve cream and aims to connect patients with dermatologists through a new virtual platform.
Arcutis appoints Christopher Peetz to its board as Class III director
Arcutis has appointed Christopher Peetz as a Class III director to its Board, effective July 15, 2026. This appointment increases the number of authorized directors from nine to ten. Mr. Peetz is the co-founder and CEO of Mirum Pharmaceuticals and has a background in various CEO and finance roles within the pharmaceutical industry.
Arcutis Biotherapeutics (Nasdaq: ARQT) names Chris Peetz to its board
Arcutis Biotherapeutics (Nasdaq: ARQT) has expanded its Board of Directors to ten members with the appointment of Christopher Peetz as a Class III independent director, effective July 15, 2026. Peetz, co-founder and CEO of Mirum Pharmaceuticals, will receive an initial option to purchase 21,486 shares, prorated annual equity awards valued at around $350,000, and a $50,000 cash retainer. The company highlighted Peetz's extensive biopharmaceutical experience and its focus on its ZORYVE roflumilast franchise for immuno-dermatology.
Arcutis Biotherapeutics appoints Chris Peetz to board
Arcutis Biotherapeutics has appointed Christopher Peetz, co-founder and CEO of Mirum Pharmaceuticals, to its board of directors, effective July 15, 2026. Peetz brings extensive biopharmaceutical experience from his previous roles at Flashlight Therapeutics, Tobira, Jennerex Biotherapeutics, and Onyx Pharmaceuticals. Arcutis, a commercial-stage immuno-dermatology company, reported strong revenue growth in Q1 2026 and continues to expand the indications for its product, ZORYVE.
